دورية أكاديمية
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
| العنوان: | Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials |
|---|---|
| المؤلفون: | Jie Liu, Annpey Pong, Silvina Gallo, Amanda Darekar, Steven G. Terra |
| المصدر: | Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019) |
| بيانات النشر: | BMC |
| سنة النشر: | 2019 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Ertugliflozin, Sodium–glucose cotransporter 2 inhibitor, Blood pressure, Systolic blood pressure, Diastolic blood pressure, Pulse rate, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| الوصف: | Background The efficacy of ertugliflozin, a sodium–glucose cotransporter 2 inhibitor, for glycemic and blood pressure (BP) control has been demonstrated in phase 3 studies. To further evaluate the effects of ertugliflozin on BP and other hemodynamic parameters, an analysis was conducted on the pooled patient populations from these studies. Methods This was a post hoc analysis of data from three phase 3 studies (NCT01958671, NCT02033889, and NCT02036515) of adults with type 2 diabetes mellitus who received placebo, ertugliflozin 5 mg, or ertugliflozin 15 mg. Outcomes at 26 weeks were analyzed for the pooled population and according to relevant baseline factors, including BP. Results Of the 1544 patients included (placebo, n = 515; ertugliflozin 5 mg, n = 519; ertugliflozin 15 mg, n = 510), most (67.4–69.0%) had hypertension at baseline. Mean baseline BP was similar across treatment groups (placebo, 129.7/78.0 mmHg; ertugliflozin 5 mg, 131.0/78.4 mmHg; ertugliflozin 15 mg, 130.5/78.4 mmHg). At Week 26, placebo-adjusted least squares (LS) mean changes (95% confidence intervals [CI]) from baseline in systolic BP (SBP) were − 3.7 mmHg (− 5.1, − 2.3) for both ertugliflozin doses. Reductions were consistent across all baseline subgroups. At Week 26, more patients with a baseline SBP ≥ 130 mmHg had a SBP < 130 mmHg with ertugliflozin (38.7% both doses) than with placebo (24.0%), and more patients with a baseline SBP ≥ 140 mmHg attained a SBP < 140 mmHg with ertugliflozin (59.5% [5 mg] and 66.7% [15 mg]) than with placebo (43.8%). Placebo-adjusted LS mean changes (95% CI) in diastolic BP (DBP) with ertugliflozin 5 mg and 15 mg were − 1.8 mmHg (− 2.7, − 0.9) and − 1.6 mmHg (− 2.5, − 0.7), respectively, and in pulse rate were − 1.3 beats per minute (bpm) (− 2.2, − 0.3) and − 1.5 bpm (− 2.5, − 0.6), respectively. Greater reductions in pulse pressure, mean arterial pressure, and double product were observed with ertugliflozin than with placebo. Incidence of adverse event-related osmotic diuresis was low, but ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1475-2840 |
| العلاقة: | http://link.springer.com/article/10.1186/s12933-019-0856-7Test; https://doaj.org/toc/1475-2840Test; https://doaj.org/article/522df3d16fb14c5b8255a70e47291d93Test |
| DOI: | 10.1186/s12933-019-0856-7 |
| الإتاحة: | https://doi.org/10.1186/s12933-019-0856-7Test https://doaj.org/article/522df3d16fb14c5b8255a70e47291d93Test |
| رقم الانضمام: | edsbas.6975C3E1 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14752840 |
|---|---|
| DOI: | 10.1186/s12933-019-0856-7 |